Literature DB >> 2018841

Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture.

C Hershko1, G Link, A Pinson, H H Peter, P Dobbin, R C Hider.   

Abstract

The ability of 3-hydroxypyridin-4-ones (CP), a family of bidentate orally effective iron chelators, to remove iron and to prevent iron-induced lipid peroxidation was studied in beating rat myocardial cells in culture. The iron (III) binding constant (log beta 3) of all CP compounds is 36, but their lipophilicity may be modified by altering the length of the R2 substituent on the ring nitrogen. There was a direct relation between lipid solubility and chelating efficiency. Although at high concentrations all CP compounds were more effective in iron mobilization than deferoxamine, the opposite was true for low concentrations. Further studies with 1,2-diethyl-3-hydroxypyridin-4-one (CP94), the most effective CP compound, have shown that iron mobilization is completed within 6 hours, that effective mobilization requires a drug: iron molar ratio exceeding 3:1 permitting the formation of a hexadentate complex, and that the beneficial effects of iron mobilization are manifested in a marked reduction in membrane lipid peroxidation as indicated by cellular malonaldehyde content. Our study represents the first demonstration of a direct interaction between myocardial cells and an orally effective iron chelator, and underlines the need for high molar concentrations for achieving an optimal therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018841

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor.

Authors:  Frank Petrat; Daniela Weisheit; Martina Lensen; Herbert de Groot; Reiner Sustmann; Ursula Rauen
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells.

Authors:  F Petrat; H de Groot; U Rauen
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

3.  Effects of chelators on iron uptake and release by the brain in the rat.

Authors:  A Crowe; E H Morgan
Journal:  Neurochem Res       Date:  1994-01       Impact factor: 3.996

4.  Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis.

Authors:  Yanhong Zhang; Xiuli Feng; Jin Zhang; Minyi Chen; Eric Huang; Xinbin Chen
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 8.756

5.  Synthesis, analysis and cytotoxic evaluation of some hydroxypyridinone derivatives on HeLa and K562 cell lines.

Authors:  L Saghaie; H Sadeghi-Aliabadi; M Ashaehshoar
Journal:  Res Pharm Sci       Date:  2013-07

Review 6.  The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain.

Authors:  Robert R Crichton; Roberta J Ward; Robert C Hider
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-17

7.  Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents.

Authors:  A Curnow; B W McIlroy; M J Postle-Hacon; J B Porter; A J MacRobert; S G Bown
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

Review 8.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

Review 9.  Is Chelation Therapy a Potential Treatment for Parkinson's Disease?

Authors:  Roberta J Ward; David T Dexter; Antonio Martin-Bastida; Robert R Crichton
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.